Equities

CannaPharmaRx Inc

CPMD:PKC

CannaPharmaRx Inc

Actions
FinancialsInvestment Banking and Brokerage Services
  • Price (USD)0.011
  • Today's Change0.00 / 0.00%
  • Shares traded59.37k
  • 1 Year change+20.88%
  • Beta--
Data delayed at least 15 minutes, as of Jul 05 2024 19:07 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

CannaPharmaRx, Inc. is focused on the acquisition and development of state-of-the-art cannabis growing facilities in Canada. The Company is engaged in producing customizable medical cannabis and craft products. Its business strategy is to produce a high quality and low-cost production of cannabis through the development, acquisition, and enhancement of existing facilities. The Company is focused on operating high-quality facilities utilizing the latest technology in combined heat and power generation to ensure being a low-cost producer of cannabis. The Company also offers a range of services to assist with cannabis inventory management.

  • Revenue in USD (TTM)25.84k
  • Net income in USD-6.61m
  • Incorporated2010
  • Employees21.00
  • Location
    CannaPharmaRx IncSuite 3600, 888 3rd Street SwCALGARY T2P 5C5CanadaCAN
  • Phone+1 (949) 652-6838
  • Fax+1 (302) 645-1280
  • Websitehttps://www.cannapharmarx.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Processa Pharmaceuticals Inc0.00-9.83m4.94m13.00--0.5562-----6.29-6.290.003.110.00----0.00-87.82-84.35-102.32-90.03------------0.0012------59.45---34.05--
Hanyuan Biotech International Inc10.65m3.14m5.28m--0.02940.00641.450.49570.22460.22460.76111.03----------------68.54--29.51--13.3625.660.00--50.51--106.71------
Stemtech Corp4.64m-4.08m5.63m45.00------1.21-0.0624-0.06240.0619-0.00921.098.3565.16103,098.40-96.70------76.09---88.58--0.1045-1.812.27--------------
SYBLEU Inc11.70k-307.88k5.92m--------505.72-0.0293-0.02930.0011-0.03670.0641-------168.63-----------2,631.45-----8.484.96--0.00--26.51------
Integrated BioPharma, Inc.50.57m-116.00k6.02m141.00--0.318328.400.119-0.0041-0.00411.670.62831.884.4510.76358,617.00-0.43115.51-0.569827.947.0912.09-0.22946.441.02-9.000.001---9.913.00-101.35---14.03--
GT Biopharma Inc0.00-9.64m6.21m2.00--0.7487-----7.04-7.040.003.850.00----0.00-64.24-205.36-90.39--------------0.00------63.62------
Sunshine Biopharma Inc26.74m-4.09m6.50m44.00--0.0138--0.243-13.35-13.3576.9624.960.90813.1311.58607,722.50-13.88-101.52-17.99-137.0433.1535.47-15.29-165.333.23--0.00--454.42--83.15--110.99--
Shuttle Pharmaceuticals Holdings Inc0.00-7.35m6.53m8.00--2.37-----0.4739-0.47390.000.16420.00----0.00-96.75---119.37-------------5.280.2542-------112.71------
Sonoma Pharmaceuticals Inc12.74m-4.84m6.84m172.00--0.9153--0.5371-0.7237-0.72371.400.39320.82242.874.6674,040.70-31.22-29.36-41.09-40.6537.2638.00-37.97-30.932.64--0.05---4.05-7.666.13---29.84--
Cannapharmarx Inc25.84k-6.61m7.29m21.00------282.02-0.0205-0.02050.00008-0.04250.0031--0.45031,230.48-79.52-131.06-----1,692.76---25,598.30--0.0033-0.1306--------143.24------
Healthy Extracts Inc2.56m-2.76m7.41m----48.86--2.89-0.9512-0.95120.88190.05120.94280.503532.10---101.47-53.78-375.65-146.6568.4645.68-107.63-87.530.1293-2.220.879--10.41105.93-151.54------
Cadrenal Therapeutics Inc-100.00bn-100.00bn7.41m3.00------------------------------------------------------------
Tonix Pharmaceuticals Holding Corp10.25m-98.59m7.87m103.00--0.017--0.7675-177.41-177.419.4646.940.0652----99,514.56-62.71-59.46-70.20-65.9237.55---961.87-5,126.730.8666--0.0767------0.1874--320.57--
Lotus Pharmaceuticals Inc70.79m1.72m8.89m233.000.05960.00092.300.12560.05530.05532.563.580.632137.2717.85303,836.901.5522.841.7126.4035.1041.622.4519.930.442830.800.05160.0028.7131.70-12.2251.1170.48--
CV Sciences Inc15.86m-3.23m9.14m42.00--3.87--0.5764-0.0207-0.02070.10120.01451.591.4227.25377,571.40-32.43-43.42-83.71-77.7545.1351.81-20.38-45.680.2677-13.320.0472---1.24-19.80133.96-20.87----
Bon Natural Life Ltd29.52m4.60m9.57m96.000.48290.07971.740.32414.994.9932.1030.230.704515.275.19307,524.6010.8614.0413.6920.6829.9430.0015.4217.622.4130.540.09550.00-1.2922.32-26.3283.09-6.70--
Data as of Jul 05 2024. Currency figures normalised to CannaPharmaRx Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.